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Fracture healing is a major clinical challenge, with a 10-20% impaired healing rate, resulting in prolonged 
hospitalizations, decreased quality of life, and substantial healthcare costs. Currently, myriad therapeutics that 
target various mechanisms and signalling pathways have been developed to augment fracture healing. Apart 
from bone morphogenic protein (BMP) implants, there are currently no FDA approved options to improve 
fracture healing. A major challenge to translation of bone-acting therapeutics is effective drug delivery, as 
systemic delivery of therapeutics is limited by short duration of action and off-target effects due to rapid 
clearance and poor bone biodistribution (<1% of injected dose). This motivates the development of polymer 
therapeutics for targeted, systemic drug delivery to bone. Design of polymeric drug conjugates and 
nanoparticles (NPs) decorated with bone-targeting peptides were developed to realize robust, specific bone 
targeting efficacy. First, poly(ethylene glycol) copolymers were synthesized with incorporation of a peptide with 
high affinity to tartrate-resistant acid phosphatase (TRAP) (TRAP-binding peptide, TBP), an enzyme deposited 
by osteoclasts during the bone resorption phase of bone remodeling, which provides high specificity relevant for 
bone cell drugging. Gradient and random peptide incorporation, as well as polymer molecular weights, were 
investigated. TRAP-targeted, high molecular weight (Mn) random copolymers exhibited superior accumulation in 
remodeling bone, where fracture accumulation was observed for at least 1 week and accounted for 14% of 
tissue distribution. Informed by these experiments, NPs were developed with high corona molecular weights 
with random peptide incorporation. Potent fracture-targeting efficiency was observed for this drug delivery 
system, and NPs accumulated at fractures for ~ 7 days (Fig. 1). NPs loaded with a small molecule bone 
anabolic Wnt/β-catenin agonist showed fracture site-specific upregulation of β-catenin signalling, enhanced 
bone mechanical properties, and faster healing rates (Fig. 1). Taken together, this drug delivery strategy 
developed here establish criteria for the design of next generation drug delivery systems for bone.    
Figure 1. TBP functionalization results in preferential NP accumulation at fracture sites and improves fracture 
healing. Live animal imaging showed qualitatively (A) and quantitatively (B) increased fracture targeting of TBP-
NPs versus untargeted NPs and SCP-NPs. N=6, mean ± std. dev., *, #, and $ indicate significant difference 
(p<0.05) versus saline, NP-IR780, and SCP-NP-IR780. (C) Live animal imaging shows tissue distribution 24 hrs 
after injection of saline, NP-IR780, SCP-NP-IR780, and TBP-NP-IR780. (D) Histological analysis of fracture 
localization of model drug IR780 delivered via TBP-NP and SCP-NP. Nuclei are stained with DAPI (blue) and 
IR780 loaded NPs fluoresce pink. (E) LacZ staining shows localized activation (arrow) of β-catenin (blue) 14 
days after injection of β-catenin agonist-loaded NPs. (F) Radiographs taken 21 days after fractures show the 
superior callus formation and healing via targeted delivery of β-catenin agonist.
